SCHEMBL16189282

SCHEMBL16189282

Cc1nc(-c2ccc(-c3cccc(-c4nc(-c5ccccc5)nc(-c5ccccc5)n4)c3)cc2)cc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.47
KMT2A Q03164 10/20 0.47
ALDH1A1 P00352 5/20 0.47
MAPT P10636 5/20 0.47
HPGD P15428 5/20 0.47
KDM4E B2RXH2 4/20 0.46
LMNA P02545 2/20 0.46
GLA P06280 1/20 0.46
NTSR1 P30989 1/20 0.44
RAC1 P63000 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
PDE10A Q9Y233 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16189308 0.94 MEN1 (0.53) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL19009532 0.93 MEN1 (0.54) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL19009659 0.88 L3MBTL1 (0.44) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL19037219 0.88 L3MBTL1 (0.47) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL7823188 0.84 ADORA3 (0.47) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL25106339 0.81 MEN1 (0.69) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL25106175 0.81 MEN1 (0.69) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL22073477 0.81 MEN1 (0.69) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL24084002 0.81 MEN1 (0.69) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL20617021 0.81 MEN1 (0.69) MEN1KMT2AALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 US disclosed
WO-2014171541-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE ELEMENT AND APPLICATION THEREFOR 東ソー株式会社 (JP) 2014-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION AOC2, AZI2, KCNH2 MEN1 2195/4885KMT2A 1481/4885ALDH1A1 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.